249 related articles for article (PubMed ID: 27185374)
41. Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis.
Ueda S; Saeki T; Osaki A; Yamane T; Kuji I
Clin Cancer Res; 2017 Oct; 23(19):5769-5778. PubMed ID: 28679773
[No Abstract] [Full Text] [Related]
42. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
[TBL] [Abstract][Full Text] [Related]
43. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
[TBL] [Abstract][Full Text] [Related]
44. Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO).
Yuan H; Frank JE; Merrill JR; Hillesheim DA; Khachaturian MH; Anzellotti AI
Curr Radiopharm; 2016; 9(3):235-243. PubMed ID: 27562785
[TBL] [Abstract][Full Text] [Related]
45. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
46. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
Cho H; Ackerstaff E; Carlin S; Lupu ME; Wang Y; Rizwan A; O'Donoghue J; Ling CC; Humm JL; Zanzonico PB; Koutcher JA
Neoplasia; 2009 Mar; 11(3):247-59, 2p following 259. PubMed ID: 19242606
[TBL] [Abstract][Full Text] [Related]
47. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
48. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
49. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging.
Carmona-Bozo JC; Manavaki R; Woitek R; Torheim T; Baxter GC; Caracò C; Provenzano E; Graves MJ; Fryer TD; Patterson AJ; Gilbert FJ
Eur Radiol; 2021 Jan; 31(1):333-344. PubMed ID: 32725330
[TBL] [Abstract][Full Text] [Related]
51. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
52. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
53. FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas.
Chakhoyan A; Guillamo JS; Collet S; Kauffmann F; Delcroix N; Lechapt-Zalcman E; Constans JM; Petit E; MacKenzie ET; Barré L; Bernaudin M; Touzani O; Valable S
Sci Rep; 2017 Aug; 7(1):10210. PubMed ID: 28860608
[TBL] [Abstract][Full Text] [Related]
54. A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.
Rockne RC; Trister AD; Jacobs J; Hawkins-Daarud AJ; Neal ML; Hendrickson K; Mrugala MM; Rockhill JK; Kinahan P; Krohn KA; Swanson KR
J R Soc Interface; 2015 Feb; 12(103):. PubMed ID: 25540239
[TBL] [Abstract][Full Text] [Related]
55. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
56. Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse.
Leimgruber A; Hickson K; Lee ST; Gan HK; Cher LM; Sachinidis JI; O'Keefe GJ; Scott AM
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1476-1485. PubMed ID: 32025750
[TBL] [Abstract][Full Text] [Related]
57.
Quintela-Fandino M; Lluch A; Manso L; Calvo I; Cortes J; García-Saenz JA; Gil-Gil M; Martinez-Jánez N; Gonzalez-Martin A; Adrover E; de Andres R; Viñas G; Llombart-Cussac A; Alba E; Guerra J; Bermejo B; Zamora E; Moreno-Anton F; Pernas Simon S; Carrato A; Lopez-Alonso A; Escudero MJ; Campo R; Carrasco E; Palacios J; Mulero F; Colomer R
Clin Cancer Res; 2017 Mar; 23(6):1432-1441. PubMed ID: 27587436
[No Abstract] [Full Text] [Related]
58. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
59. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.
Thorwarth D; Eschmann SM; Scheiderbauer J; Paulsen F; Alber M
BMC Cancer; 2005 Dec; 5():152. PubMed ID: 16321146
[TBL] [Abstract][Full Text] [Related]
60. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
